FGF2 induces imatinib resistance in patients’ CD34+ CML cells via reactivation of FGFR3-RAS-MAPK signaling (Traer et al., 2014). Here, FGFR3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.